Marathon Pharmaceuticals Names Joe Nolan Chief Commercial Officer

CHICAGO--(BUSINESS WIRE)--Marathon Pharmaceuticals, LLC, a biopharmaceutical company focused on developing treatments for rare diseases and neurological disorders, today announced that Joe Nolan has joined the company as chief commercial officer. In his new role, Mr. Nolan will oversee the commercial development, marketing and launch of Marathon's rare disease treatments.

"He will be key to the success of our upcoming rare disease product launches."
Mr. Nolan's experience in the pharmaceutical industry spans nearly three decades. Prior to joining Marathon's executive team, Mr. Nolan spent 18 years leading marketing and business development efforts for multi-billion-dollar pharmaceutical companies including Lundbeck, Takeda and Abbott, as well as 10 years working to build startups into mid-size pharmaceutical companies.

During his tenure at Lundbeck, Mr. Nolan led the company's global licensing and business development, third-party alliances, new product development, product launches and strategic business planning in the United States, including the recent acquisition and integration of Chelsea Therapeutics into the Lundbeck portfolio.

Mr. Nolan earned his Master of Business Administration degree from the University of Notre Dame and a bachelor's degree in marketing and finance from Tulane University. He has served on the board of directors for Illinois Biotechnology Industry Organization (iBIO) and the Illinois Science and Mathematics Academy (ISMA).

"Joe is a proven industry leader who can help Marathon continue to grow and deliver new rare disease treatments to the patients who need them," said Jeff Aronin, CEO of Marathon. "He will be key to the success of our upcoming rare disease product launches."

Marathon Pharmaceuticals, LLC is a biopharmaceutical company that develops new treatments for rare diseases with a focus on providing medicine to patients who currently have no treatment options. The company is developing a pipeline of treatments for rare neurological and movement disorders. Marathon is headquartered in Northbrook, Illinois, with offices in Chicago, New Jersey and Washington D.C. For more information, visit www.marathonpharma.com.

Contacts

Aileron Communications
Peter Gray, 312.629.9400
[email protected]

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.